CureHIV Seeks Funding for LiSAVIOR from Bill and Melinda Gates' Grand Challenges to Cure HIV
Dr. Roger Kenneth Hershline PhD MD, Global Humanceuticals, Inc and CureHIV apply to Bill and Melinda Gates' Grand Challenges in Global Health to fund the new HIV non-traditional drug LiSAVIOR. Current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract.
Hilton Head Island, SC, April 02, 2008 --(PR.com)-- Dr. Roger Kenneth Hershline PhD MD the CEO of Global Humanceuticals, Inc and founder and chairman of the not-for-profit public charity CureHIV.us, announces today that he is reaching out to Bill and Melinda Gates for funding from their Grand Challenges in Global Health initiative. The monies will be used to begin clinical studies of a new drug and treatment method, LiSAVIOR.
This unique new drug is also known as compound NIAID #11039 and has received a patent from the United States with patent number: 6,821,958 on November 23, 2004. Also, the World International Patent Organization published the International Application Number as
PCT/US2005/039528 on November 5, 2006. Dr. Hershline hosted Session V at the World Aids Day Conference China from December 1 to December 3, 2006, to initially present LiSAVIOR.
The proposed roadblock to cure HIV is that current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract. HIV virus multiplies and mutates in the gastrointestinal tract and then is reabsorbed into the blood. This process is known to occur when HIV infection results from the use of contaminated needles or during sexual intercourse. The gastrointestinal tract is comprised of the mouth and its structures, the pharynx, the esophagus, the stomach, the small intestines, the large intestines and the anus.
The proposed solution to overcome this roadblock is the oral clinical use of LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor that will stay in the gastrointestinal tract. LiSAVIOR blocks not only viral entry into cells but also cell-to-cell transfer of the virus. LiSAVIOR is proposed to be used alone or with any known HIV drug and vaccine therapy.
Pre-clinical efficacy testing of LiSAVIOR has shown that the effective concentration of LiSAVIOR is found to be equivalent to diluting a 1% solution of LiSAVIOR one million times. LiSAVIOR is a dry, palatable, non-toxic powder that is stable at room temperature and humidity.
“Traditional commercial drug design and projects funding from the NIH have completely ignored this approach to date. I am thinking in terms of problem solving.” Stated Dr. Hershline. "I think we have to talk in terms of a cure for HIV. I want to cure HIV and that is why my foundation is called CureHIV.us," concluded Dr. Hershline. Dr. Hershline is hopeful that the Bill and Melinda Gates and their Global Initiative funding looks into the work and progress that he has made towards solving this problem and fills the gap in funding.
Pre-clinical development of LiSAVIOR has been twenty years in the making. Despite the critical need for such a unique and potentially lifesaving invention, LiSAVIOR remains completely un-funded.
Dr. Hershline has a doctorate degree in drug design and a medical degree.
Interested parties can contact Dr. Roger Kenneth Hershline PhD MD thru
CureHIV.us Headquarters by email: Roger@CureHIV.us, mail P.O. Box 23467,
Hilton Head Is., SC, 29925, by fax: +1-843-342-5924, phone: +1-843-342-5900. Direct to Dr. Hershline: +1-843-683-3683.
Web site: http://www.curehiv.us
###
This unique new drug is also known as compound NIAID #11039 and has received a patent from the United States with patent number: 6,821,958 on November 23, 2004. Also, the World International Patent Organization published the International Application Number as
PCT/US2005/039528 on November 5, 2006. Dr. Hershline hosted Session V at the World Aids Day Conference China from December 1 to December 3, 2006, to initially present LiSAVIOR.
The proposed roadblock to cure HIV is that current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract. HIV virus multiplies and mutates in the gastrointestinal tract and then is reabsorbed into the blood. This process is known to occur when HIV infection results from the use of contaminated needles or during sexual intercourse. The gastrointestinal tract is comprised of the mouth and its structures, the pharynx, the esophagus, the stomach, the small intestines, the large intestines and the anus.
The proposed solution to overcome this roadblock is the oral clinical use of LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor that will stay in the gastrointestinal tract. LiSAVIOR blocks not only viral entry into cells but also cell-to-cell transfer of the virus. LiSAVIOR is proposed to be used alone or with any known HIV drug and vaccine therapy.
Pre-clinical efficacy testing of LiSAVIOR has shown that the effective concentration of LiSAVIOR is found to be equivalent to diluting a 1% solution of LiSAVIOR one million times. LiSAVIOR is a dry, palatable, non-toxic powder that is stable at room temperature and humidity.
“Traditional commercial drug design and projects funding from the NIH have completely ignored this approach to date. I am thinking in terms of problem solving.” Stated Dr. Hershline. "I think we have to talk in terms of a cure for HIV. I want to cure HIV and that is why my foundation is called CureHIV.us," concluded Dr. Hershline. Dr. Hershline is hopeful that the Bill and Melinda Gates and their Global Initiative funding looks into the work and progress that he has made towards solving this problem and fills the gap in funding.
Pre-clinical development of LiSAVIOR has been twenty years in the making. Despite the critical need for such a unique and potentially lifesaving invention, LiSAVIOR remains completely un-funded.
Dr. Hershline has a doctorate degree in drug design and a medical degree.
Interested parties can contact Dr. Roger Kenneth Hershline PhD MD thru
CureHIV.us Headquarters by email: Roger@CureHIV.us, mail P.O. Box 23467,
Hilton Head Is., SC, 29925, by fax: +1-843-342-5924, phone: +1-843-342-5900. Direct to Dr. Hershline: +1-843-683-3683.
Web site: http://www.curehiv.us
###
Contact
CureHIV Global Humanceuticals, Inc.
Roger Hershline
843-683-3683
www.CureHIV.us
Roger Hershline
843-683-3683
www.CureHIV.us
Contact
Categories